LCTC 最新10-Q变化
将 LCTC 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-05-14 与上一份 10-Q · 2025-11-12
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +96 | −59 | ~23 | 13 |
| 市场风险(第3项) | 文字有新增/删除 | +106 | −53 | ~13 | 12 |
| 控制与程序 | 文字有新增/删除 | +106 | −53 | ~13 | 12 |
| 法律诉讼 | 文字有新增/删除 | +106 | −53 | ~13 | 12 |
| 风险因素 | 部分风险因素更新 | +106 | −53 | ~13 | 12 |
| 其他信息 | 文字有新增/删除 | +106 | −53 | ~12 | 12 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-05-14
ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 16
ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 17
Real-time Alcohol Detection And Recognition equipment and software 569,448 569,448
Production equipment, software and space modifications 1,366,539 1,366,539
Office equipment, software and space modifications 197,686 197,686
相对上期删除的文字 · 来源:10-Q · 2025-11-12
The following is a discussion of our financial condition and results of operations, and should be read in conjunction with our financial statements and the related notes included elsewhere in this Form 10-Q. Certain statements contained in this section are not historical facts, including statements …
Lifeloc Technologies, Inc., a Colorado corporation ("Lifeloc" or the "Company"), is a leading developer, manufacturer and marketer of portable hand-held and fixed station breathalyzers, now focused on expanding our offerings into technologies for the detection of drugs of abuse.
In 2016, we obtained exclusive rights to develop and commercialize Sandia National Laboratories’ patented SpinDx™ technology for drugs of abuse. Lifeloc has adapted this technology platform which uses centrifugal disk and microfluidics technology to enable rapid, on-site, and cost-effective drug tes…
The SpinDetect™ analyzer is designed to address key limitations in existing drug-testing methods. Its ability to resolve psychoactive delta-9-THC from inactive metabolites supports more accurate assessments of recent use and potential impairment - an important differentiator in marijuana testing, wh…
The platform can be adapted to detect a wide range of substances, and we are actively negotiating an expansion of our license to include applications beyond current drug-testing markets. Potential future applications include the detection of biological hazards such as listeria and salmonella.
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-05-14
Subordinated debentures payable, current portion 34,522 33,371
TERM LOAN PAYABLE, net of current portion and debt issuance costs 1,044,449 1,058,426
SUBORDINATED DEBENTURES PAYABLE, net of current portion and debt issuance costs 672,274 681,343
Condensed Statements of Changes in Stockholders’ Equity (Unaudited)
Common Stock Shares Common Stock Amount Accumulated Deficit Total
相对上期删除的文字 · 来源:10-Q · 2025-11-12
shares outstanding (2,664,116 outstanding at December 31, 2024)
Condensed Statements of Changes in Stockholders' Equity (Unaudited)
Common Stock Shares Common Stock Amount Retained Earnings (Accumulated Deficit) Total
Purchases of research and development equipment, software and
Proceeds from Issuance of shares from option exercise 336,300 —
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-05-14
Subordinated debentures payable, current portion 34,522 33,371
TERM LOAN PAYABLE, net of current portion and debt issuance costs 1,044,449 1,058,426
SUBORDINATED DEBENTURES PAYABLE, net of current portion and debt issuance costs 672,274 681,343
Condensed Statements of Changes in Stockholders’ Equity (Unaudited)
Common Stock Shares Common Stock Amount Accumulated Deficit Total
相对上期删除的文字 · 来源:10-Q · 2025-11-12
shares outstanding (2,664,116 outstanding at December 31, 2024)
Condensed Statements of Changes in Stockholders' Equity (Unaudited)
Common Stock Shares Common Stock Amount Retained Earnings (Accumulated Deficit) Total
Purchases of research and development equipment, software and
Proceeds from Issuance of shares from option exercise 336,300 —
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-05-14
Subordinated debentures payable, current portion 34,522 33,371
TERM LOAN PAYABLE, net of current portion and debt issuance costs 1,044,449 1,058,426
SUBORDINATED DEBENTURES PAYABLE, net of current portion and debt issuance costs 672,274 681,343
Condensed Statements of Changes in Stockholders’ Equity (Unaudited)
Common Stock Shares Common Stock Amount Accumulated Deficit Total
相对上期删除的文字 · 来源:10-Q · 2025-11-12
shares outstanding (2,664,116 outstanding at December 31, 2024)
Condensed Statements of Changes in Stockholders' Equity (Unaudited)
Common Stock Shares Common Stock Amount Retained Earnings (Accumulated Deficit) Total
Purchases of research and development equipment, software and
Proceeds from Issuance of shares from option exercise 336,300 —
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-05-14
Subordinated debentures payable, current portion 34,522 33,371
TERM LOAN PAYABLE, net of current portion and debt issuance costs 1,044,449 1,058,426
SUBORDINATED DEBENTURES PAYABLE, net of current portion and debt issuance costs 672,274 681,343
Condensed Statements of Changes in Stockholders’ Equity (Unaudited)
Common Stock Shares Common Stock Amount Accumulated Deficit Total
相对上期删除的文字 · 来源:10-Q · 2025-11-12
shares outstanding (2,664,116 outstanding at December 31, 2024)
Condensed Statements of Changes in Stockholders' Equity (Unaudited)
Common Stock Shares Common Stock Amount Retained Earnings (Accumulated Deficit) Total
Purchases of research and development equipment, software and
Proceeds from Issuance of shares from option exercise 336,300 —
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-05-14
Subordinated debentures payable, current portion 34,522 33,371
TERM LOAN PAYABLE, net of current portion and debt issuance costs 1,044,449 1,058,426
SUBORDINATED DEBENTURES PAYABLE, net of current portion and debt issuance costs 672,274 681,343
Condensed Statements of Changes in Stockholders’ Equity (Unaudited)
Common Stock Shares Common Stock Amount Accumulated Deficit Total
相对上期删除的文字 · 来源:10-Q · 2025-11-12
shares outstanding (2,664,116 outstanding at December 31, 2024)
Condensed Statements of Changes in Stockholders' Equity (Unaudited)
Common Stock Shares Common Stock Amount Retained Earnings (Accumulated Deficit) Total
Purchases of research and development equipment, software and
Proceeds from Issuance of shares from option exercise 336,300 —
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议